ReviewCurrent hypertension reports2013
Pharmacologic treatment options for obesity: what is old is new again.
Review in Current hypertension reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04725058 (Obesity Group Visits. A Novel Way to Approach the Obesity Epidemic in an Inner-City Setting), which is not on this map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Obesity Group Visits. A Novel Way to Approach the Obesity Epidemic in an Inner-City Setting
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Efficacy of Probiotics in Overweight and Obesity Control: An Umbrella Review and Subgroup Meta-Analysis.Probiotics and antimicrobial proteins · 2024Pooled it
- Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.Drug design, development and therapy · 2014Pooled it
- Long-term drug treatment for obesity: a systematic and clinical review.JAMA · 2014 · on this mapPooled it
- Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study.International journal of obesity (2005) · 2020Article
- Article
- Anti-obesogenic and antidiabetic effects of plants and mushrooms.Nature reviews. Endocrinology · 2017Review
- Greater hunger and less restraint predict weight loss success with phentermine treatment.Obesity (Silver Spring, Md.) · 2016Observational
- Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies.International journal of obesity (2005) · 2016Observational
- Review
- The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease.Reviews in endocrine & metabolic disorders · 2015Review
- Review
- Effectiveness of 6 months of tailored text message reminders for obese male participants in a worksite weight loss program: randomized controlled trial.JMIR mHealth and uHealth · 2015Article
- Pharmacotherapy for obesity: novel agents and paradigms.Therapeutic advances in chronic disease · 2014Review
- Botanicals and translational medicine: a paradigm shift in research approach.Nutrition (Burbank, Los Angeles County, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After a long period of failure in development, two new medications (phentermine/topiramate ER - Qsymia™ and lorcaserin - Belviq®) have been approved by the US Food and Drug Administration for long-term weight management in persons with obesity (BMI ≥ 30 kg/m(2)) or in overweight persons (BMI ≥ 27 kg/m(2)) with comorbidities. Another medication, bupropion/naltrexone, is undertaking a cardiovascular outcomes trial and an analysis in 2014 will determine its approval and release. The most widely prescribed drug for obesity, phentermine, used since 1959 for short-term weight management, has been released in a new formulation. This paper reviews these new medications, and other important events in the landscape for management of obesity, with an eye to the interests of physicians who manage hypertension. All the new drugs under discussion are re-fittings of old agents or fresh approaches to old targets; thus, what is old is new again in the pharmacotherapy of obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.